c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition

Cancer Biology and Therapy

Volumn 12, Issue 6, 2011, Pages 531-538

  Carr, Brian I ^a   Wang, Ziqiu ^a   Wang, Meifang ^a   Cavallini, Aldo ^a   D'Alessandro, Rosalba ^a   Refolo, Maria Gratzia ^a  

^a De Bellis Medical Research Institute   (Italy)

Author keywords

Akt; c Met phosphorylation; DEP 1 protein phosphatase; Raf protein kinase; Sorafenib; Vitamin K1

Indexed keywords

PHYTOMENADIONE; PROTEIN KINASE B; RAF PROTEIN; SCATTER FACTOR RECEPTOR; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC TRANSFECTION; GROWTH INHIBITION; LIVER CELL CARCINOMA; NONHUMAN; PLASMID; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIETHYLNITROSAMINE; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LIVER NEOPLASMS, EXPERIMENTAL; MAP KINASE KINASE KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; VITAMIN K 1;

EID: 80052834805     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.6.16053     Document Type: Article

References (36)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID: 18650514; DOI: 10.1056/NEJMoa0708857.
2. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-40; PMID: 18852116; DOI: 10.1158/1535-7163.MCT-08-0013.
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109; PMID: 15466206; DOI: 10.1158/0008- 5472.CAN-04-1443.
4. Krueger T, Westenfeld R, Schurgers L, Brandenburg V. Coagulation meets calcification: the vitamin K system. Int J Artif Organs 2009; 32:67-74; PMID: 19363777.
5. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 2007; 39:239-47; PMID: 17909264; DOI: 10.1677/JME-07-0048.
6. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40:243-51; PMID: 15239108; DOI: 10.1002/hep.20260.
7. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F, et al. The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 2008; 28:45-50; PMID: 18383823.
8. Ma M, Qu XJ, Mu GY, Chen MH, Cheng YN, Kokudo N, et al. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gammacarboxy prothrombin. Chemotherapy 2009; 55:28-35; PMID: 18974646; DOI: 10.1159/000167022.
9. Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, et al. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27:505-11; PMID: 16010434.
10. Matsumoto K, Okano J, Nagahara T, Murawaki Y. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol 2006; 29:1501-8; PMID: 17088989.
11. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 2002; 22:3237-46; PMID: 11971957; DOI: 10.1128/MCB.22.10. 3237-46.2002.
12. Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 1994; 13:1610-9; PMID: 8157000.
13. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan P, Brautigan DL, et al. Raf-1 activates MAP kinasekinase. Nature 1992; 358:417-21; PMID: 1322500; DOI: 10.1038/358417a0.
14. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal 2003; 15:463-9; PMID: 12639709; DOI: 10.1016/S0898- 6568(02)00139-0.
15. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9:174-9; PMID: 9069260; DOI: 10.1016/S0955-0674(97)80060-9.
16. Schramm K, Niehof M, Radziwill G, Rommel C, Moelling K. Phosphorylation of c-Raf-1 by protein kinase A interferes with activation. Biochem Biophys Res Commun 1994; 201:740-7; PMID: 8003010; DOI: 10.1006/bbrc.1994.1763.
17. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (Protein kinase B). Science 1999; 286:1741-4; PMID: 10576742; DOI: 10.1126/ science.286.5445.1741.
18. Keane MM, Lowrey G, Ettenberg S, Dayton M, Lipkowitz S. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res 1996; 56:4236-43; PMID: 8797598.
19. Palka HL, Park M, Tonks NK. Hepatocyte growth factor receptor tyrosine kinase Met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 2003; 278:5728-35; PMID: 12475979; DOI: 10.1074/jbc.M210656200.
20. Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by auto-phosphorylation. Mol Cell Biol 1991; 11:1793-803; PMID: 2005882.
21. Zhu H, Naujokas MA, Fixman ED, Torossian K, Park M. Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis. J Biol Chem 1994; 269:29943-8; PMID: 7961992.
22. Hartmann G, Weidner KM, Schwarz H, Birchmeier W. The motility signal of scatter factor/hepatocyte growth factor through the receptor tyrosine kinase Met requires intracellular action of Ras. J Biol Chem 1994; 269:21936-9; PMID: 8071312.
23. Ponzetto C, Bardelli A, Zhen Z, Maina F, Dalla Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77:261-71; PMID: 7513258; DOI: 10.1016/0092-8674(94)90318-2.
24. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, et al. Induction of epithelial tubules by growth factor HGF depends on STAT pathway. Nature 1998; 391:285-8; PMID: 9440692; DOI: 10.1038/34657.
25. Royal I, Park M. Hepatocyte growth factor-induced scatter of Madin-Darby Canine kidney cells requires phosphatidylinositol-3-kinase. J Biol Chem 1995; 270:27780-7; PMID: 7499247; DOI: 10.1074/ jbc.270.46.27780.
26. Liu ML, Mars WM, Michalopoulos GK. Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. Carcinogenesis 1995; 16:841-3; PMID: 7728965; DOI: 10.1093/carcin/16.4.841.
27. Webster CR, Anwer MS. Phosphoinositide-3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 2001; 33:608-15; PMID: 11230741; DOI: 10.1053/jhep.2001.22756.
28. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide- 3-kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89:457-67; PMID: 9150145; DOI: 10.1016/S0092-8674(00)80226-3.
29. Wang Z, Wang M, Carr BI. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway. J Cell Physiol 2005; 203:510-9; PMID: 15534860; DOI: 10.1002/ jcp.20243.
30. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of Sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 2010; 127:2949-58; PMID: 21351273; DOI: 10.1002/ijc.25498.
31. + hepatocytes by DEN. Carcinogenesis 1989; 10:2107-11; PMID: 2805231; DOI: 10.1093/carcin/ 10.11.2107.
32. Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54:2073-7; PMID: 18251162.
33. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292:358-61; PMID: 15265851; DOI: 10.1001/jama.292.3.358.
34. Sidovar MF, Kozlowski P, Lee JW, Collins MA, He Y, Graves LM. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J Biol Chem 2000; 275:28688-94; PMID: 10862777; DOI: 10.1074/jbc. M909351199.
35. Wang Z, Wang M, Carr BI. Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in Sorafenib-induced cytoskeletal rearrangement in hepatoma cells. J Cell Physiol 2010; 224:559-65; PMID: 20432459; DOI: 10.1002/ jcp.22160.
36. Kweon S, Park KA, Choi H. Chemopreventive effect of garlic powder diet in diethylnitrosamine-induced rat hepatocarcinogenesis. Life Sci 2003; 73:2515- 26; PMID: 12954459; DOI: 10.1016/S0024- 3205(03)00660-X.